Answers are grounded in this paper and cite their sources.
Cross-sectional study characterizes premarket clinical evidence for moderate-risk therapeutic devices, indicating the effectiveness of the De Novo pathway.
This cross-sectional study characterizes the premarket clinical evidence supporting clearance of moderate-risk novel therapeutic medical devices by the US Food and Drug Administration.
No takes yet. Share an insight, caveat, or question.
Johnston et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: